Section Arrow
Quote
UNCY.NASDAQ
- Unicycive Therapeutics Inc
Quotes are at least 15-min delayed:2026/10/18 19:14 EDT
Regular Hours
Last
 3.36
-0.23 (-6.41%)
Day High 
3.595 
Prev. Close
3.59 
1-M High
4.97 
Volume 
1.10M 
Bid
3.26
Ask
3.4
Day Low
3.35 
Open
3.58 
1-M Low
3.56 
Market Cap 
100.00M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.01 
20-SMA 4.37 
50-SMA 4.89 
52-W High 8.74 
52-W Low 3.56 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.75/2.30
Enterprise Value
100.00M
Balance Sheet
Book Value Per Share
1.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.06
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.465-0.695-16.71%-- 
TCRTAlaunos Therapeutics Inc.2.63+0.45+20.64%-- 
IBRXImmunityBio9.18-0.82-8.20%-- 
MRNAModerna218.01-18.49-7.82%-- 
SLSSELLAS Life Sciences Group9.98-1.36-11.99%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two keyproduct candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.